|Articles|July 27, 2023
DIA 2023: What is Biofourmis Currently Working on with CancerX?
Advertisement
In an interview at the 2023 DIA annual meeting with ACT editor, Andy Studna, Jaydev Thakkar, chief operating officer, Biofourmis, disucsses how Biofourmis is working with CancerX to address the financial burden cancer treatment can place on patients.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Workflow in the Age of AI
2
The AI Churn Trap in Life Sciences and How to Break It
3
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
4
ACT Brief: Data Readiness Gap in Continuous Monitoring, Workflow-Centric AI Deployment, and First-in-Class ADHD Mechanism
5